Tandem Diabetes Care (TNDM) Cash from Operations Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.65 Bn | 175.35 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.95 Bn | 126.08 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.30 Bn | 99.08 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.31 Bn | 66.85 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.97 Bn | 26.39 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 0.50% |
| 10 | Tandem Diabetes Care | 1.14 Bn | 570.61 Mn | 136.79 Mn | 37.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.56% |
| Dec 31, 2025 | 18.92% |
| Sep 30, 2025 | -29.85% |
| Jun 30, 2025 | -50.02% |
| Mar 31, 2025 | -49.25% |
| Dec 31, 2024 | -18.28% |
| Sep 30, 2024 | -7.78% |
| Jun 30, 2024 | -29.71% |
| Mar 31, 2024 | -31.59% |
| Dec 31, 2023 | -35.24% |
| Sep 30, 2023 | -84.43% |
| Jun 30, 2023 | -34.03% |
| Mar 31, 2023 | 3.87% |
| Dec 31, 2022 | -33.11% |
| Sep 30, 2022 | 1.32% |
| Jun 30, 2022 | 24.59% |
| Mar 31, 2022 | 74.86% |
| Dec 31, 2021 | 11.58% |
| Sep 30, 2021 | 128.16% |
| Jun 30, 2021 | 84.67% |